|

SHR-8068 Clinical Trials

6 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 1Phase 1/2: 5

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.4
  • Shanghai Hengrui Pharmaceutical Co., Ltd.1
  • Fudan University1

Indications

  • Cancer6
  • Lung Cancer2
  • HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer1
  • Recurrent or Metastatic Cervical Cancer1
  • Non-small Cell Lung Cancer (NSCLC)1

Other6 trials

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1/2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Phase 1/2
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1/2
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/2
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.